Market Overview:
The global dravet syndrome therapeutics market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of dravet syndrome, rising awareness about dravet syndrome, and increasing research and development activities for the treatment of dravet syndrome. However, the high cost of therapies is expected to restrain the growth of this market during the forecast period. The global dravet syndrome therapeutics market can be segmented on the basis of type, application, and region.
Product Definition:
Dravet Syndrome Thereapeutics is a medication used to treat Dravet syndrome, a rare and severe form of epilepsy. Dravet syndrome is caused by mutations in the SCN1A gene, which codes for the sodium channel protein NaV1.1. These mutations result in excessive neuronal firing and seizures. The goal of treatment with Dravet Syndrome Thereapeutics is to reduce seizure frequency and severity.
BIS-001:
Bis-001 is a drug developed by the British firm, Sunesis Pharmaceuticals Ltd. for the treatment of Dravet Syndrome (a type of epilepsy). The company applied for FDA approval to market Bis-001 in 2014 and received it in 2016.
Cannabidiol:
Cannabidiol (CBD) is one of the many chemical compounds found in the cannabis plant.
Application Insights:
Based on the application, the global Dravet syndrome therapeutics market is segmented into a clinic, hospital and others. The Others segment held the largest share in 2017 as it includes online pharmacies and mail order pharmacies. Online pharmacy dispensing medication without visiting doctor¢â‚¬â„¢s office is gaining popularity due to less time consumed in traveling and cost-effectiveness. Furthermore, increasing number of prescriptions filled through mail order or over the internet without any medical consultation is expected to boost growth during forecast period. However, hospital based treatment holds highest revenue share as compared to other segments owing to presence of highly skilled manpower along with advanced healthcare facilities that ensure better treatment for patients suffering from Dravet syndrome.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable government policies and funding programs are some factors responsible for its growth. For instance, in December 2016, the U.S. FDA approved a new drug application for Epidiolex-based treatment of Dravet syndrome. In addition to this, GW Pharmaceuticals received orphan drug approval from EMEA in 2015 for its CBD product GWP42004/Sativex as an add-on therapy for epilepsy patients resistant to anti-epileptic drugs (AED).
Asia Pacific is expected to be the fastest growing region over the forecast period owing to increasing number of cases due to rising awareness about these disorders and supportive government initiatives such as funds provided by BIS-001 FUJIBAID® (bendbuterol) program initiated by Ministry of Health Labor and Welfare (Japan).
Growth Factors:
- Increasing incidence of Dravet Syndrome
- Growing awareness about Dravet Syndrome among people
- Rising demand for better treatment options for Dravet Syndrome patients
- Availability of government funding for research on Dravet Syndrome therapies
- Technological advancements in the field of epilepsy therapeutics
Scope Of The Report
Report Attributes
Report Details
Report Title
Dravet Syndrome Thereapeutics Market Research Report
By Type
BIS-001, Cannabidiol, CUR-1916, SAGE-217, Others
By Application
Clinic, Hospital, Others
By Companies
Biscayne Pharmaceuticals, Inc., GW Pharmaceuticals Plc, INSYS Therapeutics, Inc., OPKO Health, Inc., PTC Therapeutics, Inc., Sage Therapeutics, Inc., Xenon Pharmaceuticals Inc., Zogenix, Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
121
Number of Tables & Figures
85
Customization Available
Yes, the report can be customized as per your need.
Global Dravet Syndrome Thereapeutics Market Report Segments:
The global Dravet Syndrome Thereapeutics market is segmented on the basis of:
Types
BIS-001, Cannabidiol, CUR-1916, SAGE-217, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Biscayne Pharmaceuticals, Inc.
- GW Pharmaceuticals Plc
- INSYS Therapeutics, Inc.
- OPKO Health, Inc.
- PTC Therapeutics, Inc.
- Sage Therapeutics, Inc.
- Xenon Pharmaceuticals Inc.
- Zogenix, Inc.
Highlights of The Dravet Syndrome Thereapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- BIS-001
- Cannabidiol
- CUR-1916
- SAGE-217
- Others
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Dravet Syndrome Thereapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Dravet syndrome is a rare, severe form of epilepsy that begins in early infancy. Epilepsy is a condition in which the brain doesn't work correctly. seizures are episodes of uncontrolled shaking or convulsions caused by abnormal electrical activity in the brain. Dravet syndrome occurs when seizures occur more than 30 times per day and last for at least 3 hours.
Some of the key players operating in the dravet syndrome thereapeutics market are Biscayne Pharmaceuticals, Inc., GW Pharmaceuticals Plc, INSYS Therapeutics, Inc., OPKO Health, Inc., PTC Therapeutics, Inc., Sage Therapeutics, Inc., Xenon Pharmaceuticals Inc., Zogenix, Inc..
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Dravet Syndrome Thereapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Dravet Syndrome Thereapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Dravet Syndrome Thereapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Dravet Syndrome Thereapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Dravet Syndrome Thereapeutics Market Size & Forecast, 2020-2028
4.5.1 Dravet Syndrome Thereapeutics Market Size and Y-o-Y Growth
4.5.2 Dravet Syndrome Thereapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 BIS-001
5.2.2 Cannabidiol
5.2.3 CUR-1916
5.2.4 SAGE-217
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Clinic
6.2.2 Hospital
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Dravet Syndrome Thereapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Dravet Syndrome Thereapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 BIS-001
9.6.2 Cannabidiol
9.6.3 CUR-1916
9.6.4 SAGE-217
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Clinic
9.10.2 Hospital
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 BIS-001
10.6.2 Cannabidiol
10.6.3 CUR-1916
10.6.4 SAGE-217
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Clinic
10.10.2 Hospital
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 BIS-001
11.6.2 Cannabidiol
11.6.3 CUR-1916
11.6.4 SAGE-217
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Clinic
11.10.2 Hospital
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 BIS-001
12.6.2 Cannabidiol
12.6.3 CUR-1916
12.6.4 SAGE-217
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Clinic
12.10.2 Hospital
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 BIS-001
13.6.2 Cannabidiol
13.6.3 CUR-1916
13.6.4 SAGE-217
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Clinic
13.10.2 Hospital
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Dravet Syndrome Thereapeutics Market: Competitive Dashboard
14.2 Global Dravet Syndrome Thereapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Biscayne Pharmaceuticals, Inc.
14.3.2 GW Pharmaceuticals Plc
14.3.3 INSYS Therapeutics, Inc.
14.3.4 OPKO Health, Inc.
14.3.5 PTC Therapeutics, Inc.
14.3.6 Sage Therapeutics, Inc.
14.3.7 Xenon Pharmaceuticals Inc.
14.3.8 Zogenix, Inc.
